Additionally, it is possible that CD44+CD133+ tumor-initiating cells from primary xenografts have an enhanced ability to respond to tumor microenvironmental signals via dynamic interactions with their microenvironment in secondary xenografts. The gene discussed is CD44; the disease is neoplasm.